A 63-year-old woman presented with right retro-orbital plasmacytoma. Magnetic resonance imaging (MRI; Fig 1A) confirmed a large, solid, well-delineated mass in the right orbit that was displacing the eyeball and upper extrinsic muscles downwards, without cerebral parenchyma involvement. Linear pachy-meningeal thickening extended to the right supraorbital and frontal dura, suggesting dural infiltration. The patient underwent fronto-temporal craniotomy. Histology and immunohistochemistry of the mass showed massive immunoglobulin (Ig) G-j plasma cell infiltration with 20% Ki-67 plasma cells. Bone marrow biopsy indicated 35% infiltration of monoclonal IgG-j plasma cells. Cerebral spinal fluid (CSF) was normal. Blood tests, including b2-microglobulin, were normal except for total protein (62 g/l), hypogammaglobulinaemia (4 g/l) and the presence of an IgG-j monoclonal component by serum immunofixation. Bence Jones protein was undetectable. A skeletal X-ray showed small osteolytic areas in the cranial vault and frontal–parietal area. Multiple myeloma (MM) was diagnosed. The patient underwent three cycles of Cy-VAD (cyclophosphamide, vincristine, adriamycin, dexamethasone) chemotherapy but, before the fourth, presented with a persistent headache. A MRI scan showed MM dural involvement. The CSF cell count was 18/mm with plasma cells and plasmablasts. Polymerase chain reaction amplification of IGH showed a monoclonal rearrangement in CSF. Meningeal myelomatosis was diagnosed. The patient received two intrathecal pushes of 50 mg liposomal cytarabine (SkyePharma, London, UK) at a 14-d interval, and dexamethasone (8 mg twice daily for 14 d). Her fever and headache rapidly disappeared. One month after encephalic radiotherapy (total dose 30 Gy), two more pushes of liposomal cytarabine were administered. Dexamethasone, radiotherapy and four injections of liposomal cytarabine were well tolerated. 18 months after diagnosis, disease assessment showed no serum monoclonal component, rare plasma cells in the bone marrow and no mass on cranial MRI (Fig 1B). Multiple myeloma involvement of the central nervous system is rare (Damaj et al, 2004; Fassas et al, 2004) and the outcome is extremely poor despite aggressive local and systemic treatment including high-dose chemotherapy (Pizzuti et al, 1997; Patriarca et al, 2001). As our patient had already been treated with dexamethasone in first-line treatment, intrathecal liposomal cytarabine alone seemed to ensure successful eradication of meningeal myelomatosis.